Long-Term Results from the IDEAL-CRT Phase 1/2 Trial of Isotoxically Dose-Escalated Radiation Therapy and Concurrent Chemotherapy for Stage II/III Non-small Cell Lung Cancer

PURPOSE: The IDEAL-CRT phase 1/2 multicenter trial of isotoxically dose-escalated concurrent chemoradiation for stage II/III non-small cell lung cancer investigated two 30-fraction schedules of 5 and 6 weeks’ duration. We report toxicity, tumor response, progression-free survival (PFS), and overall...

Descripción completa

Detalles Bibliográficos
Autores principales: Fenwick, John D., Landau, David B., Baker, Angela T., Bates, Andrew T., Eswar, Chinnamani, Garcia-Alonso, Angel, Harden, Susan V., Illsley, Marianne C., Laurence, Virginia, Malik, Zafar, Mayles, William Philip M., Miles, Elizabeth, Mohammed, Nazia, Spicer, James, Wells, Paula, Vivekanandan, Sindu, Mullin, Anne-Marie, Hughes, Laura, Farrelly, Laura, Ngai, Yenting, Counsell, Nicholas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier, Inc 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7049901/
https://www.ncbi.nlm.nih.gov/pubmed/31809876
http://dx.doi.org/10.1016/j.ijrobp.2019.11.397

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7049901/
https://www.ncbi.nlm.nih.gov/pubmed/31809876
http://dx.doi.org/10.1016/j.ijrobp.2019.11.397

Ejemplares similares